Mark Ator

Mark Ator is an accomplished professional in the field of pharmacology and drug metabolism with extensive experience in leadership roles across multiple organizations. Currently serving as AVP of Discovery DMPK at Parabilis Medicines since January 2024, Mark has previously held significant positions including VP of DMPK and Pharmacology at Psivant Therapeutics and Executive Director of Preclinical Development at Roivant Sciences. With a background that includes VP of Preclinical Development at Oncopia Therapeutics and Senior Director roles at both Teva Pharmaceuticals and Cephalon, Mark has a strong foundation in molecular and cellular pharmacology. Mark's academic credentials include a B.S. in Chemistry from the University of Virginia, a Ph.D. in Biochemistry from the University of Wisconsin-Madison, and postdoctoral work at the University of California, San Francisco.